Data Monitoring Committees — Expect the Unexpected
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
I n the five decades since the completion of the Greenberg Report recommendations in 1967 (which were later published 1 ), independent groups of experts have monitored the progress of many clinical trials for early definitive evidence of benefit, convincing evidence of harm, or sufficient evidence of no potential benefit to render continuation of the trial to be futile.Such monitoring is motivated primarily by an ethical imperative; for trials of treatments intended to prevent or delay serious outcomes, one would want to stop the trial and make the superior treatment available as soon as the evidence was definitive.The assessment of risk versus benefit throughout the course of the trial requires frequent access to accumulating data on efficacy and safety.To allow investigators and sponsors to manage the trial without bias, as well as to ensure an objective assessment of the accumulating data, independent committees, known as data monitoring committees (DMCs), data and safety monitoring boards, or other aliases, 2 are established to perform this monitoring function and to make recommendations regarding trial modifications, including early termination, to investigators and sponsors.These committees require multidisciplinary expertise and experience, including knowledge of statistical methods for interim data monitoring; they also pay attention to recruitment progress and the general quality of the trial with respect to adherence to the protocol and completeness of data collection and follow-up.Data are typically reviewed by DMCs according to the intervention groups as randomized; these groups should be identified fully, perhaps as "group A and group B," in the printed report, in which the identities of groups A and B are known by the DMC.[2][3][4] After the data have been reviewed, DMCs make a recommendation to the trial steering committee that the trial continue as planned or be terminated early for the reasons noted above (see Table 1 for a summary of DMC responsibilities).The Coronary Drug Project, an early, large cardiovascular trial sponsored by what was at that time known as the National Heart Institute, was probably the first trial to incorporate interim review by independent experts 5 and provided many lessons regarding the DMC process.6,7 This process continued to evolve and became the general approach for most federally sponsored randomized trials during the 1970s 2,8,9 and eventually for the increasing number of phase 3 industry-sponsored trials, 10 with some modification of the National Institutes of Health (NIH) model.11 The evolution of DMCs continues as the art and science of clinical trial performance itself evolves.In most cases, trials are completed as planned, with no DMC recommendation for early termination or major modification, but some trials have raised challenging issues for DMCs.[12][13][14][15][16][17][18][19] In this article, we briefly summarize a few classic cases of early termination and then address some recent cases to further illustrate the complexity of the responsibilities of the DMCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
The agonising negative trend in monitoring of clinical trials
DeMets, D. L., Pocock, S. J., & Julian, D. G. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03464-9 · Cited by 126
Self-citation
Cited by
Adaptive designs in clinical trials: why use them, and how to run and report them
Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., Holmes, J., Mander, A. P., Odondi, L., Sydes, M. R., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1017-7 · Cited by 829
Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative
Calis, K. A., Archdeacon, P., Bain, R., DeMets, D., Donohue, M., Elzarrad, M. K., Forrest, A., McEachern, J., Pencina, M. J., Perlmutter, J., et al. (2017) · Clinical Trials · doi:10.1177/1740774517707743 · Cited by 58
Self-citationWu, T., Bian, Z., Shang, H., & Li, Y. (2017) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12268 · Cited by 13
Metadata
- Authors
- DeMets, D. L., & Ellenberg, S. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-10-06
- Volume
- 375
- Issue
- 14
- Pages
- 1365-1371
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2529207539
- Cited by
- 72
- References
- 7
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Data Monitoring Committees — Expect the Unexpected. https://app.cochat.ai/papers/10.1056/nejmra1510066
- The paper
- DeMets, D. L., & Ellenberg, S. S. (2016). Data Monitoring Committees — Expect the Unexpected. New England Journal of Medicine. https://doi.org/10.1056/nejmra1510066
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.